GlassScriptPhysician profile
Kelli N Dahlgren
NPI 1821518200
$11,213.05
in general payments reported to CMS, 2019-2025
38 companies · $7,226 in 2025
The $7,226 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $240 · 2023: $733 · 2024: $2,799 · 2025: $7,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,910 · Consulting Fee: $3,000 · Travel and Lodging: $760 · Education: $87.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,910.18 |
| Consulting Fee | $3,000.00 |
| Travel and Lodging | $760.24 |
| Education | $87.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $3,638.04 | 2024-2025 | |
| Novo Nordisk INC | $1,205.83 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $1,039.11 | 2022-2025 | Korlym |
| Lilly USA, LLC | $737.02 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Medtronic, INC. | $648.13 | 2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $432.41 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.45 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Mannkind Corporation | $356.21 | 2023-2025 | Afrezza |
| Novartis Pharmaceuticals Corporation | $297.84 | 2023-2025 | |
| Amgen INC. | $274.42 | 2024-2025 | Tepezza, Repatha, Repatha |
| Recordati_rare_diseases_inc. | $250.54 | 2024-2025 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $249.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbott Laboratories | $178.20 | 2024-2025 | Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $131.27 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $128.43 | 2023-2025 | Tymlos |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $124.04 | 2023 | Quviviq |
| Dexcom, INC. | $124.02 | 2023-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $112.10 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $106.24 | 2024-2025 | Nexletol |
| Ascendis Pharma Endocrinology INC | $102.07 | 2025 | Yorvipath |
| Angiodynamics, INC. | $86.29 | 2024 | Auryon Laser System 100-120 Vac |
| Abbvie INC. | $82.50 | 2024-2025 | |
| Nevro Corp. | $79.11 | 2022 | |
| Amneal Pharmaceuticals LLC | $71.38 | 2025 | Unithroid |
| Intercept Pharmaceuticals, INC. | $64.42 | 2022 | |
| Insulet Corporation | $63.17 | 2024-2025 | Omnipod |
| Beta Bionics, INC. | $33.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $31.99 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $31.10 | 2023 | |
| Chiesi USA, INC. | $22.53 | 2024 | Mycapssa |
| Sanofi-Aventis U.S. LLC | $21.35 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.24 | 2021 | |
| Ibsa Pharma INC. | $20.74 | 2025 | Flector, Licart, Tirosint |
| Horizon Therapeutics Plc | $20.05 | 2023 | Tepezza |
| Glaxosmithkline, LLC. | $19.33 | 2025 | Shingrix, Arexvy |
| Henry Schein, INC. | $16.84 | 2024 | |
| Cequr Corporation | $13.62 | 2022 | |
| Merck Sharp & Dohme LLC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Dahlgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.